Crohn's Disease: key endpoint results by drug
The key endpoints of Crohn's Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Crohn's Disease page.
Clinical remission (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 37.3% | 6.8% | +30.5 | 160/80 mg · wk 4 · n 102 | NCT02499783 Phase 3, primary |
| certolizumab pegol | 31.6% | 25.4% | +6.2 | wk 6 · n 215 | NCT00552058 Phase 3, primary |
| duvakitug | 54.3% | 41.3% | +13 | 900 mg · wk 14 · n 46 | NCT05499130 Phase 2b, secondary |
| filgotinib | 39.3% | 22.2% | +17.1 | 200 mg · wk 10 · n 28 | NCT03046056 Phase 2, secondary |
| infliximab | 47.3% | 34.1% (Azathioprine + Placebo) | — | wk 10 · n 169 | NCT00094458 Phase 3, secondary |
| mirikizumab | 37.7% | 25.1% | +12.6 | wk 12 · n 579 | NCT03926130 Phase 3, secondary |
| ozanimod | 29.8% | 30.5% | −0.7 | wk 12 · n 403 | NCT03440385 Phase 3, primary |
| risankizumab | 42% | 19.8% | +22.2 | 600 mg · wk 12 · n 191 | NCT03104413 Phase 3, primary |
| tofacitinib | 43.0% | 36.7% | +6.4 | 10 mg BID · wk 8 · n 86 | NCT01393626 Phase 2, primary |
| upadacitinib | 49.5% | 29.1% | +20.4 | 45 mg QD · wk 12 · n 350 | NCT03345849 Phase 3, primary |
| ustekinumab | 15.9% | 7.3% | +8.6 | 130 mg · wk 8 · n 245 | NCT01369329 Phase 3, secondary |
| vedolizumab | 14.5% | 6.8% | +7.7 | wk 6 · n 220 | NCT00783692 Phase 3, primary |
Drugs checked with no result here: 9 trial running, 57 not reported, 2 not posted.
Endoscopic response (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| duvakitug | 47.8% | 13% | +34.8 | 900 mg · wk 14 · n 46 | NCT05499130 Phase 2b, primary |
| mirikizumab | 32.5% | 12.6% | +19.9 | wk 12 · n 579 | NCT03926130 Phase 3, secondary |
| risankizumab | 28.8% | 11.2% | +17.6 | 600 mg · wk 12 · n 191 | NCT03104413 Phase 3, primary |
| upadacitinib | 45.5% | 13.1% | +32.4 | 45 mg QD · wk 12 · n 350 | NCT03345849 Phase 3, primary |
Drugs checked with no result here: 11 trial running, 5 not posted, 60 not reported.
Clinical remission (maintenance)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 38.1% | 9.1% | +29 | 40 mg Eow · wk 52 · n 21 | NCT00445432 Phase 2/3, primary |
| adalimumab-adbm (Cyltezo) | 68.6% | 76.2% (Humira EU) | — | wk 24 · n 68 | NCT02871635 Phase 3, secondary |
| certolizumab pegol | 37.5% | 35% | +2.5 | wk 34 · n 16 | NCT00356408 Phase 3, secondary |
| filgotinib | 42.9% | 28.3% | +14.6 | 200 mg · wk 58 · n 112 | NCT02914561 Phase 3, primary |
| infliximab | 66% | 54.7% (Azathioprine + Placebo) | — | wk 50 · n 97 | NCT00094458 Phase 3, secondary |
| mirikizumab | 54.1% | 19.6% | +34.5 | wk 52 · n 579 | NCT03926130 Phase 3, secondary |
| tofacitinib | 41.9% | 28.6% | +13.3 | 10 mg BID · wk 26 · n 43 | NCT01393899 Phase 2, secondary |
| ustekinumab | 53.1% | 35.9% | +17.2 | 90 mg SC q8w · wk 44 · n 128 | NCT01369355 Phase 3, primary |
| vedolizumab | 48% | 34.3% | +13.7 | 108 mg SC · wk 52 · n 275 | NCT02611817 Phase 3, primary |
Drugs checked with no result here: 12 trial running, 57 not reported, 2 not posted.
Endoscopic response (maintenance)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| filgotinib | 30.4% | 9.4% | +21 | 200 mg · wk 58 · n 112 | NCT02914561 Phase 3, primary |
| mirikizumab | 48.4% | 9% | +39.4 | wk 52 · n 579 | NCT03926130 Phase 3, secondary |
| ustekinumab | 23.5% | 16% (Ustekinumab) | — | q4w · wk 48 · n 51 | NCT04245215 Phase 3, secondary |
Drugs checked with no result here: 14 trial running, 4 not posted, 59 not reported.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 80 approved or late-stage drugs with a featured trial in Crohn's Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.